SG Americas Securities
CDTX

SG Americas Securities’s Cidara Therapeutics CDTX Stock Holding History

SG Americas Securities’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,257
Closed -$1.16M – 3282
2025
Q4 		$1.16M Buy
5,257
+3,632
+224% +$587K ﹤0.01% 1892
2025
Q3 		$156K Buy
+1,625
New +$104K ﹤0.01% 2883
2020
Q3 		– Sell
-901
Closed -$67K – 2790
2020
Q2 		$67K Buy
+901
New +$58.4K ﹤0.01% 3478

SG Americas Securities's CDTX Position: Q1 2026 in Review

SG Americas Securities sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 5,257 shares — an estimated $1.16M sold.

SG Americas Securities first reported a position in CDTX in Q2 2020 and held it in 3 quarters. The position peaked at $1.16M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

  • SG Americas Securities reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SG Americas Securities sold 5,257 Cidara Therapeutics shares in Q1 2026, an estimated $1.16M.
  • SG Americas Securities first reported a position in Cidara Therapeutics in Q2 2020 and held it in 3 quarters.
  • SG Americas Securities's Cidara Therapeutics position peaked at $1.16M in Q4 2025.
  • 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.